Boston-An injectable tissue-augmenting material is a promising alternativefor the endoscopic treatment of vesicoureteral reflux in children, accordingto researchers from Dublin, Ireland. At follow-up of up to 1 year, refluxwas corrected in 86% of ureters after a single injection of the material,dextranomer/hyaluronic acid copolymer (Deflux, Q-Med, Uppsala, Sweden),according to lead author Prem Puri, MD, pediatric surgeon and director ofresearch at the National Children Hospital in Dublin.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Drug extends survival in prostate cancer with genetic mutations
December 8th 2023“Our analysis suggests that there is superior clinical benefit with olaparib versus control both in patients who had and had not received previous taxane treatment,” said Maha Hussain, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University.